Wegovy's path since its FDA approval in 2021 has been marked by one consistent problem: demand has dramatically outpaced supply. At its peak, the shortage was so severe that Novo Nordisk suspended new patient acceptance entirely. Pharmacies across the country had waiting lists.
The good news heading into 2026 is that Novo Nordisk has significantly scaled manufacturing. The formal FDA shortage designation for semaglutide was removed. But "officially not in shortage" and "easy to get" are not the same thing — and the regulatory landscape for alternatives has shifted substantially in the same period. Here is where things actually stand.
Why the Wegovy Shortage Happened
Understanding the shortage helps contextualize why alternatives emerged and whether they remain viable.
Demand That Overwhelmed Manufacturing
Wegovy launched in June 2021 to immediate, overwhelming demand. GLP-1 medications had never been available for weight management at this efficacy level, and coverage of the STEP trials generated interest that exceeded any forecast. Novo Nordisk's existing semaglutide manufacturing capacity — built primarily to supply Ozempic for diabetes patients — was simply not designed for this scale.
The supply chain problem was further complicated by the specialized chemistry involved. Semaglutide is a peptide drug — its synthesis requires protected amino acid chains, purification processes, and fill-finish operations that cannot be stood up quickly. Manufacturing capacity must be built years in advance.
The Compounding Response
During the shortage, the FDA's drug shortage designation triggered a legal window for compounding pharmacies to manufacture copies of the shortage drug. Compounded semaglutide — typically sold as a vial-and-syringe injectable at a fraction of Wegovy's brand price — proliferated rapidly through telehealth platforms.
By 2023–2024, dozens of GLP-1 telehealth companies were offering compounded semaglutide, typically for $99–$299/month, making it accessible to patients who could not afford Wegovy's $1,300+ monthly list price or lacked insurance coverage.
The Regulatory Shift in 2025
In early 2025, the FDA removed semaglutide from its official drug shortage list. This triggered a series of actions:
- The FDA notified compounding pharmacies that shortage-based compounding of semaglutide copies would no longer be automatically protected
- 503B outsourcing facilities (large-scale compounders) faced stricter restrictions
- 503A pharmacies (traditional, individual-patient compounders) continued operating but under evolving regulatory scrutiny
The regulatory picture remains dynamic. Legal challenges from compounders, prescribers, and patient advocates have complicated enforcement timelines. As of 2026, the landscape varies by provider type, state, and specific product formulation.
Where Wegovy Availability Stands in 2026
Wegovy is generally more available than it was in 2022–2024. Novo Nordisk expanded manufacturing significantly, and the drug is stocked at major pharmacy chains in most markets. However:
- Starter doses (0.25mg, 0.5mg) remain inconsistent. New patients initiating Wegovy may encounter stockouts at specific pharmacies. Calling ahead or checking GoodRx's availability tracker before filling can save significant frustration.
- Regional variation persists. Urban markets with high GLP-1 prescribing volume may still see shortfalls, while rural or lower-volume markets often have better availability.
- Insurance access bottlenecks are separate from supply. Many patients who cannot "get" Wegovy are actually facing coverage denials, prior authorization delays, or prohibitive cost — not true supply shortage.
If your pharmacy doesn't have your dose, try:
- Calling 3–5 additional pharmacies directly (don't rely solely on online availability tools)
- Asking your prescriber for a days' supply bridge or dose substitution
- Using a specialty pharmacy that works specifically with GLP-1 medications
Your Alternatives: What's Actually Available
Option 1: Zepbound (Tirzepatide for Weight Loss)
Zepbound received FDA approval for chronic weight management in November 2023. It is the weight-specific formulation of Mounjaro (tirzepatide) from Eli Lilly.
Why it matters as a Wegovy alternative: The SURMOUNT-5 head-to-head trial demonstrated that tirzepatide 10–15mg produced 20.2% mean weight loss compared to 13.7% for Wegovy over 72 weeks — a clinically and statistically significant difference. For patients who couldn't get Wegovy or had a partial response to semaglutide, Zepbound is the evidence-based next step.
Availability has generally been better than Wegovy since launch. Eli Lilly built manufacturing capacity with the shortage lesson in mind.
Option 2: Compounded Semaglutide (Where Available)
Compounded semaglutide remains the most price-accessible option in markets where it is legally available. If you are currently taking compounded semaglutide through a telehealth platform, verify that your provider is operating within current FDA guidelines — ask them directly about their pharmacy's regulatory status.
For patients who have never started but want to access compounded semaglutide, availability depends significantly on your state and the platform you use. Some platforms have navigated the regulatory shift; others have discontinued offering compounded semaglutide in response to FDA guidance.
Option 3: Compounded Tirzepatide
Compounded tirzepatide followed a similar legal path as semaglutide — it became available during the Mounjaro shortage period. As of 2026, availability varies by platform and state regulation. Where available, pricing is typically $150–$450/month, making it more accessible than brand-name Zepbound.
Option 4: Saxenda (Liraglutide)
Saxenda (liraglutide, Novo Nordisk) is an older GLP-1 receptor agonist FDA-approved for chronic weight management. It requires daily injection versus Wegovy's weekly dosing and produces somewhat less weight loss (approximately 5–8% on average vs. ~15% for Wegovy).
Saxenda is available and generically more accessible than newer agents for some patients with specific insurance coverage situations. It is not the first choice for patients who prioritize maximum efficacy, but it is a legitimate option for those who cannot access newer agents.
Option 5: Non-GLP-1 Medications
For patients who cannot access any GLP-1 medication, alternatives include:
- Qsymia (phentermine/topiramate ER): FDA-approved, produces 6–9% average weight loss
- Contrave (naltrexone/bupropion SR): FDA-approved, produces approximately 5–8% weight loss
- Phentermine (short-term, controlled substance): older stimulant-based medication with more limited long-term data
None of these alternatives match the weight loss efficacy of GLP-1 medications at their approved doses.
Provider Comparison Table
| Provider | Drug Offered | Approx. Price | Availability |
|---|---|---|---|
| Hims / Hers | Compounded semaglutide, brand referrals | $99–$299/mo | Wide; verify current status |
| Ro | Compounded semaglutide, Wegovy | $99–$449/mo | Wide; verify current status |
| Found | Compounded semaglutide, tirzepatide | $99–$399/mo | Varies by state |
| LifeMD | Compounded semaglutide, Wegovy, Zepbound | $99–$499/mo | Wide |
| Calibrate | Behavioral program + GLP-1 prescribing | $149–$399/mo | Varies |
| Henry | Semaglutide/tirzepatide compounds | $299–$450/mo | Most states |
| Traditional pharmacy (CVS, Walgreens, Costco) | Brand Wegovy, Zepbound (Rx required) | $1,000–$1,400/mo | Varies by location |
Pricing is approximate and changes frequently. Always verify current pricing and drug availability directly with the provider. This table reflects general market patterns as of Q1 2026 and is not a ranking or endorsement.
What to Do Right Now
If you're currently on Wegovy and having trouble refilling:
- Ask your pharmacist to check neighboring stores or partner with a specialty pharmacy
- Ask your prescriber if a temporary dose hold or switching to Ozempic (same molecule, diabetes indication) is clinically appropriate while you resolve supply
- Use GoodRx's pharmacy availability feature before driving anywhere
If you've never started and want a GLP-1:
- Compare telehealth platforms using our provider quiz — filter by medication type and your state
- Ask explicitly about regulatory status if choosing compounded semaglutide — a reputable provider will give you a clear answer
- Consider Zepbound as an alternative if tirzepatide is clinically appropriate and accessible — it often has better supply than Wegovy
If cost is the primary barrier:
- Compounded options (where available) remain the most accessible price point
- Check Novo Nordisk's NovoCare and Eli Lilly's Lilly Cares programs for patient assistance
- Some employer health plans have expanded GLP-1 coverage in 2025–2026 — review your benefits
This article reflects the regulatory and supply situation as of Q1 2026. Drug availability and compounding regulations change frequently. Always consult a licensed healthcare provider before starting, switching, or stopping any GLP-1 medication. This article does not constitute medical or legal advice.